Heart :: Approval to start US BTT pivotal trial
Ventracor has received approval from the US Food & Drug Administration to begin enrolment in the US Bridge To Transplant (BTT) Pivotal Trial of the VentrAssist Left Ventricular Assist Device (LVAD).
Ventracor has received approval from the US Food & Drug Administration to begin enrolment in the US Bridge To Transplant (BTT) Pivotal Trial of the VentrAssist Left Ventricular Assist Device (LVAD).
As the diagnostic capability of MRI continues to advance, and as the availability of MRI machines increases worldwide, so should the availability of implantable devices that are MRI safe. This advance is urgently needed says one executive.
As reported in the May issue of Psychological Science, men who increased over time in neuroticism died earlier, mostly from cancer and heart disease.
Each year an estimated 20 million children are born with low birth weight worldwide, more than 95% of them in developing countries.
The common painkiller, ibuprofen, may boost the likelihood of heart problems in high risk patients who have osteoarthritis, suggests research published ahead of print in the Annals of the Rheumatic Diseases.
Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), provides comment on a re-analysis of pooled data from both hormone therapy arms of the Women?s Health Initiative (WHI) Study published in the Journal of the American Medical Association.
Binghamton University Professor Gary D. James is hoping his new book will take the stress out of researching stress. Offering guidance on topics ranging from the best ways to collect saliva and urine to working with special populations including pregnant women and the elderly, James expects that the book will help students and professionals design more effective field studies and models for stress measurement.
A Saint Louis University physician-scientist and author of a new book on how herbs, supplements, foods, vitamins and medications affect the body is researching whether an omega-3 fatty acid found in certain fish slows the progression of Alzheimer’s disease.
Theravance, Inc. (NASDAQ: THRX) announced the results of two studies in an ongoing Phase 2b clinical program to assess the efficacy and safety of the investigational bronchodilators GSK642444 (‘444) and GSK159797 (‘797), the lead long-acting Beta2 agonist (LABA) compounds in the Beyond Advair collaboration with GlaxoSmithKline (GSK).
Unchecked antisocial behaviour in boys may lead to much greater costs than previously thought, according to new research showing a link to poor adult physical health.